EUCTR2010-020515-37-GB进行中（未招募）1 期
A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 5,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Patients eligible for inclusion in this study have to fulfill all of the following criteria:
- •1. Written informed consent must be obtained before any assessment is performed.
- •2. Patients who have completed designated ongoing or planned Novartis global clinical trials with fingolimod and are unable to obtain fingolimod outside a clinical trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients fulfilling any of the following criteria are not eligible for inclusion in this study:
- •1. Premature permanent discontinuation from any fingolimod study due to:
- •a. An adverse event or serious adverse event or laboratory abnormality.
- •b. Conditions leading to permanent study drug discontinuation. Patients who temporarily or permanently discontinued from any fingolimod study because of pregnancy can be re-enrolled.
- •2. Pregnant or nursing (lactating) women where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/ml).
- •Patients who temporarily or permanently discontinued from any fingolimod study because of pregnancy can be re-enrolled.
- •3. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, UNLESS they are using highly effective contraception during the study and for 2 months after stopping treatment. 'Highly effective contraception' defined as contraception which results in less than 1% unwanted pregnancies when used properly according to the label.
- •Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least 6 weeks prior to baseline. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
- •4. Chronic disease of the immune system other than MS which may require immunosuppressive treatment.
- •5. Severe active infection or active chronic infection
- •6. Previous treatment with cladribine, cyclophosphamide or mitoxantrone.
- •7. Treatment with monoclonal antibodies (including Natalizumab) in the past 3 months.
- •8. Uncontrolled diabetes (HbA1c>9%).
- •9. Macular edema at Baseline.
- •10. Any medically unstable condition that may interfere with the patient’s ability to cooperate and comply with the study procedures, as assessed by the treating physician.
- •11. Any of the following cardiovascular conditions:
- •a. myocardial infarction within the past 6 months prior to enrollment or current unstable ischaemic heart disease
- •b. cardiac failure at time of Screening (Class III & IV, according to New York Heart Association Classification) or any severe cardiac disease as determined by the investigator.
- •c. patients receiving current treatment with Class Ia or III antiarrhythmic drugs (e.g., quinidine, disopyramide, amiodarone, bretylium, sotalol, ibulitide, azimilide, dofelitide, ajmaline, procainamide)
- •d. second-degree AV block Type II or third degree AV block or corrected QTc interval >450 msec in males or 470 msec in females;
- •e. sick sinus syndrome or sino-atrial heart block
- •f. uncontrolled hypertension despite prescribed medications
- •12. Any of the following pulmonary conditions during the previous fingolimod study o
研究者
相似试验
进行中（未招募）
1 期
ong-term safety and tolerability study of 0.5 mg fingolimod once daily in patients with relapsing forms of multiple sclerosisMedDRA version: 18.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersmultiple sclerosisEUCTR2010-020515-37-IEovartis Pharma Services AG5,000
已完成
3 期
A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis (CFTY720D2399- LONGTERMS)MS10029305multiple sclerosisNL-OMON47187ovartis95
进行中（未招募）
1 期
ong-term safety, tolerability and efficacy study of 0.5 mg fingolimod once daily in patients with multiple sclerosisEUCTR2010-020515-37-BEovartis Pharma Services AG5,000
进行中（未招募）
1 期
ong-term safety and tolerability study of 0.5 mg fingolimod once daily in patients with relapsing forms of multiple sclerosisMedDRA version: 18.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disordersmultiple sclerosisEUCTR2010-020515-37-PTovartis Pharma Services AG4,125
进行中（未招募）
1 期
A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis.Relapsing multiple sclerosisMedDRA version: 13.1 Level: PT Classification code 10048393 Term: Multiple sclerosis relapse System Organ Class: 10029205 - Nervous system disordersEUCTR2010-020515-37-NOovartis Pharma Services AG4,125